[Answered] For a two-tailed test at 86.12 confidence, Z = a. 1.96 b. 1.48 c. 1.09 d. ...

This topic contains a solution. Click here to go to the answer

Author Question: For a two-tailed test at 86.12 confidence, Z = a. 1.96 b. 1.48 c. 1.09 d. ... (Read 84 times)

Themember4

Hero Member
Posts: 538

on: Jun 24, 2018

For a two-tailed test at 86.12 confidence, Z =
a. 1.96
b. 1.48
c. 1.09
d. 0.86

Question 2

If a hypothesis is rejected at 95 confidence, it
a. will always be accepted at 90 confidence
b. will always be rejected at 90 confidence
c. will sometimes be rejected at 90 confidence
d. None of these alternatives is correct.

Need homework help now?

Ask unlimited questions for free

Ask a Question

Marked as best answer by a Subject Expert

fdliggud

Sr. Member
Posts: 366

Reply #1 on: Jun 24, 2018

Answer to Question 1

B

Answer to Question 2

B

Themember4

Member
Posts: 538

Reply 2 on: Jun 24, 2018

TYSM

Alyson.hiatt@yahoo.com

Member
Posts: 354

Reply 3 on: Yesterday

Thanks for the timely response, appreciate it

« previous next »

Did you know?

Fatal fungal infections may be able to resist newer antifungal drugs. Globally, fungal infections are often fatal due to the lack of access to multiple antifungals, which may be required to be utilized in combination. Single antifungals may not be enough to stop a fungal infection from causing the death of a patient.

Did you know?

The Babylonians wrote numbers in a system that used 60 as the base value rather than the number 10. They did not have a symbol for "zero."

Did you know?

Acute bronchitis is an inflammation of the breathing tubes (bronchi), which causes increased mucus production and other changes. It is usually caused by bacteria or viruses, can be serious in people who have pulmonary or cardiac diseases, and can lead to pneumonia.

Did you know?

Nitroglycerin is used to alleviate various heart-related conditions, and it is also the chief component of dynamite (but mixed in a solid clay base to stabilize it).

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.